Malignant Melanoma: A pictorial review by McCourt, Collette et al.
Malignant Melanoma: A pictorial review
McCourt, C., Dolan, O., & Gormley, G. (2014). Malignant Melanoma: A pictorial review. Ulster Medical Journal,
83(2), 103-110.
Published in:
Ulster Medical Journal
Document Version:
Early version, also known as pre-print
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:16. Feb. 2017
 1 
Title of manuscript:  
Malignant Melanoma: A Pictorial Review  
 
Authors: 
Collette McCourt
1
, Olivia Dolan
1
 and Gerry J Gormley
2
 
 
Affiliations: 
1
Department of Dermatology,Belfast Health and Social Care Trust, 
Belfast, Northern Ireland; 
2 
Department of General Practice, Queen’s University 
Belfast, Dunluce Health Centre, 1 Dunluce Avenue, Belfast BT9 7HR. 
 
 
Corresponding Author: 
Dr Collette McCourt, 
Department of Dermatology, 
Belfast Health and Social Care Trust, 
Belfast 
E-mail: collette.mccourt@belfasttrust.hscni.net 
 
 
Acknowledgements: 
 
We would like to acknowledge David McCallum (Head of Department of Medical 
Illustration) and the Department of Medical Illustration, Royal Victoria Hospital, 
Belfast Health and Social Care Trust for their contribution of clinical photographs 
towards the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Malignant Melanoma: A Pictorial Review  
 
Overview 
 
Introduction 
Malignant melanoma (MM) is a malignancy of pigment-producing cells 
(melanocytes), which are located primarily in the skin, but also found in the ears, 
gastrointestinal tract, eyes, oral and genital mucosa and leptomeninges.  For the 
purpose of this review the focus will be on malignant melanoma (hereby referred to as 
melanoma) affecting the skin i.e. cutaneous melanoma.  Despite the fact that 
melanoma is the least common form of skin cancer (accounting for approximately 4% 
of all new cancer cases in UK), it has the highest mortality rate with more than 2000 
deaths UK wide in 2011.
 (1)
 In Northern Ireland (NI) numbers of melanoma have 
increased from 103 cases per year in 1984–1992, to 258 per year in 2004–2009. (2)  In 
addition, the risk of a second cancer has shown to be increased in patients in NI 
following the diagnosis of melanoma.
 (3)
 The incidence continues to rise worldwide 
and whilst some of the increase may be due to increased surveillance and earlier 
detection, most are considered to be linked to changes in sun-related behaviour e.g. 
increase in frequency of holidays abroad over time and the use of sunbeds.
 (4-7)
  
 
The diagnosis of MM can have devastating consequences for a patient and their 
relatives. Early detection of MM has been shown to significantly improve survival.
 (8)
 
 
In this review we will discuss pathophysiology and risk factors with a focus on 
history, examination and differential diagnosis.  Assessment tools to aid early 
detection are reviewed and referral pathways based on how and when to refer to 
secondary care will be discussed briefly. 
 
Pathophysiology 
The sequence of events whereby normal melanocytes transform into melanoma cells 
(melanogenesis) is not fully understood.  It is most likely due to a multistep process of 
genetic mutations that alter the cell cycle and render the melanocytes more 
susceptible to the carcinogenic effects of UVR.
 (9)
 Different pathways are likely to be 
involved in different subtypes of MM, for example superficial spreading MM 
(SSMM) is known to be associated with acute intermittent sun exposure and a high 
propensity to higher naevus counts. 
 (10,11)
 In contrast lentigo maligna melanoma 
(LMM) more often occurs on chronically sun-exposed skin. 
 (11)
 
 
Classification 
Melanoma can be classified into 4 different clinical subtypes: superficial spreading 
melanoma (SSMM), lentigo maligna melanoma, nodular melanoma and acral 
lentiginous melanoma (characterized by the site of origin; palm, sole or subungal).  
Malignant melanoma in-situ and lentigo maligna are considered premalignant lesions. 
 
SSSM 
Commonly displays the ABCDE warning signs 
(12)
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Table 1. 
 
ABCDEs of melanoma 
A 
B 
C 
D 
E 
Asymmetry 
Border irregularity 
Colour variation 
Diameter > 6mm 
Evolving (changing) 
 
It tends to present as a flat or slightly elevated brown lesion with variegated 
pigmentation (i.e. black, blue, pink or white discoloration) with an irregular shape 
often > 6mm. 
 
a)    b)  
 
Image 1 (a) Malignant melanoma –asymmetrical lesion with irregular borders and variegated 
pigment + (b) Dermoscopy image –irregular broad pigment network with radiating streaks at 
periphery of lesion 
 
 
Lentigo maligna (lentigo maligna melanoma) 
Lentigo maligna melanoma presents as a slowing growing or changing patch of 
discoloured skin with variegated shape and colour. They often show slow progressive 
changes from in situ lentigo maligna (LM) to invasive LMM and may be detected 
using the ABCDE rule.  
 
 
Image 2. Lentigo maligna – irregularly pigmented patch with irregular borders 
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Nodular melanoma 
A nodular melanoma may arise on any site, but is most common on exposed areas of 
the head and neck and usually presents as a rapidly enlarging lump (weeks to 
months).  One third of nodular melanomas are amelanotic i.e. non-pigmented and may 
be ulcerated. This can often lead to diagnostic difficulty. However any new ulcerated 
nodular skin lesion should alert the clinician to the high possibility of skin cancer. 
 
 
 
Image 3. Non-pigmented erythematous telangiectatic nodule at site of previous lentigo maligna 
melanoma 
 
 
Acral lentiginous melanoma 
This type of melanoma starts as a slowly enlarging flat patch of discoloured skin and 
tends to follow the ABCDE rule.  Although initially smooth at first, it later becomes 
thicker with an irregular surface. 
 
SSMM is by far the most common clinical subtype of melanoma in white skin and 
accounts for approximately 70% of cases diagnosed.  In contrast, acral lentiginous 
melanoma is the least common subtype in white patients, more often seen in patients 
with African-American skin types.  This is thought to be due to different genetic 
mutations, with kit mutations occurring in more of the later 
(13)
 and up to 50% SSMM 
demonstrating BRAF mutations.
 (13)
 Some of the newer treatments for metastatic MM 
target these mutations.  There are also clear gender differences with regard to site of 
occurrence. Melanoma occurs most commonly on the trunk in white males 
(approximately 40% of cases) and the lower legs (approximately 43%) in white 
females.
 (14)
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Figure 1. 
 
 
Differential diagnosis 
The differential of melanoma is wide and includes benign lesions such as seborrhoeic 
keratosis, benign melanocytic naevi, blue naevi and vascular lesions e.g. spider 
angiomas and pyogenic granulomas.  Pre-malignant or malignant differentials include 
dysplastic naevi, squamous cell carcinoma, pigmented basal cell carcinoma and 
pigmented actinic keratosis.  
 
Seborrhoeic keratosis 
These lesions usually appear as slightly raised, skin coloured or brown spots, which 
gradually thicken and develop a rough warty surface.  Over time they may darken to 
become dark brown to black.  A clue to their diagnosis is the ‘stuck on’ appearance. 
 
a)   b)  
 
Image 4 (a) Clinical appearance of seborrhoeic keratosis – stuck on appearance  (b) Dermoscopy 
image – cerebriform appearance and lack of pigment network 
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Pyogenic granuloma 
These lesions appear as small red papules that grow rapidly (weeks) and usually bleed 
easily and ulcerate.  They are common in children and young adults, may follow 
trauma and most frequently appear on the head, neck, upper trunk and hands (fingers) 
and feet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a)                b)       
   
 
Image 5. a) Friable vascular nodule on the base of the thumb b) close up 
 
 
Benign melanocytic naevus 
These can be divided into congenital or acquired (junctional, dermal, compound 
types) naevi.  They are regular and symmetrical with uniform pigment. 
 
 
 
Image 6. Benign melanocytic naevus.  Regular, symmetrical and uniformly pigmented lesion. 
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Dysplastic/atypical naevus 
Unusual appearance with at least 3 of the following features: blurred or ill-defined 
borders, irregular shape, variegated colour, flat and raised components or size 6mm or 
more. 
 
 
 
Image 7. Dysplastic naevus – irregularly shaped darkly pigmented naevus.  ‘Ugly duckling.’ 
 
Cherry angioma 
These lesions usually develop on the trunk and can appear red or blue/black in colour.  
Cherry angiomas usually increase in number in middle-aged individuals and are 
otherwise known as Campbell de Morgan spots. 
 
a)  b)  
 
Image 8 (a) Clinical image of cherry angioma with vascular appearance (b) Dermoscopic image – 
vascular lagunes visable. 
 
 
Pigmented basal cell carcinoma 
These tumours are typically slow growing over months to years.  The pigmented type 
may mimic melanoma. 
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a)  b)  
 
Image 9 (a) + (b) Pigmented basal cell carcinoma. Pearly telangietatic nodules. Note peripheral 
pigmentation at bottom left in (a) and along right lateral edge in (b). 
 
 
Dermatofibroma 
These are benign slow growing dermal nodules, often occurring on the limbs.  
Although they may have a pigmented halo, they are symmetrical, helping distinguish 
them from melanoma. 
 
 
Who is at risk of melanoma? 
Clinical history and careful skin examination will assist the clinician in identifying 
those most at risk of developing melanoma. 
 
 
History  
Seven point checklist 
When assessing a patient with a new or changing lesion the history is extremely 
important.  There are several assessment tools available for assessing risk, one of 
which in widespread use is the Glasgow 7-point checklist 
(15) 
 which awards 2 points 
to any of the major criteria; change in size, change in colour and change in shape with 
1 point awarded to any of the following; ooze, change in sensation, inflammation or 
diameter >7mm.  A score of 3 points or any one criterion with strong concerns about 
cancer should prompt a red flag referral to the dermatology service in secondary care. 
(16)
   
 
Table 2. Glasgow 7-point checklist 
 
Major features Minor features 
 Change in size (2) 
 Irregular shape (2) 
 Irregular colour (2) 
 
 Diameter > 7mm (1) 
 Inflammation (1) 
 Oozing (1) 
 Change in sensation (1) 
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ABCDE rule 
Another commonly used tool for early detection of melanoma is the ABCDE acronym 
(Asymmetry, Border irregularity, Colour variegation, Diameter >6mm and Evolution 
or history of change) introduced to alert patients and health professionals to the 
diagnosis of melanoma. 
(12)
  
 
Table 3. 
 
Northern Ireland Cancer Network (NICaN) Referral Guidelines for Suspected 
Skin Cancer 
Urgent referral: 
 Melanoma: change in a lesion is a key element in diagnosing malignant 
melanoma.  Do not excise in primary care. Lesions scoring 3 points or more 
(as below) are suspicious. 
 Major features of lesions 
 Change in size 
 Irregular shape 
 Irregular colour 
 Minor features 
 Diameter >7 mm 
 Inflammation/oozing 
 Change in sensation 
Squamous cell carcinomas: non-healing keratinizing or crusted tumours >1 cm in 
diameter with induration on palpation.  Commmonly on face, scalp or back of hand; 
with documented expansion over 8 weeks 
New or growing cutaneous lesions after organ transplant – squamous cell carcinoma 
common with immunosuppression 
Histological diagnosis of squamous cell carcinoma 
Basal cell carcinomas can be referred non-urgently 
 
 
 
It is important to be aware that although melanoma may develop in precursor 
melanocytic naevi (e.g. congenital naevi), up to 70% of cases are believed to arise de 
novo (ie, not from a preexisting pigmented lesion).   In addition, for nodular and 
amelanotic subtypes, these algorithms are less accurate.  In these cases the ‘ugly 
duckling’ sign may be more useful, whereby the melanoma can be recognised as an 
‘outlier’ by differing clinical appearances. (17)  
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Skin type and Naevi Count 
The most important phenotypic markers for melanoma are fair skin and above-
average mole count.  
 
Table 4. 
 
Recommendation (adapted from the The prevention, diagnosis, referral and 
management of melanoma of the skin: concise guidelines. 2007) 
1. Identifying people at risk 
People should be considered to have higher risk (approximately 10-fold) if they 
have: 
 >100 normal moles 
 atypical moles 
 two or more cases of melanoma in first-degree relatives. 
 
Lower (approximately 2- to 3- fold) levels of risk are associated with: 
 freckles 
 red hair or skin that burns in the sun 
 any family history of melanoma. 
 
2. Primary prevention 
 People at risk of skin cancer should protect their skin from the sun by 
avoidance and clothing primarily. 
 They should also use a sun protection factor (SPF) of 20 to 30, and five star 
ultraviolet A (UVA) 
 
3. Secondary prevention 
 People who are in any of these higher risk (10-fold) categories above should 
be referred for risk estimation and education directed towards self-
examination with a dermatologist specializing in moles and pigmented 
lesions (routine appointment) 
 Base-line photography is a useful aid to monitoring moles 
 
4. Urgent referral to a dermatologist 
The following should be regarded as suspicious lesions requiring urgent referral 
to a dermatologist within 2 weeks: 
 a new mole which is growing quickly over the age of puberty 
 a long-standing mole which is changing progressively in shape or colour 
regardless of age 
 any mole which has 3 more more colours or has lost its symmetry 
 any new nodule which is growing and is pigmented or vascular in 
appearance 
 a new pigmented line in a nail 
 something growing under a nail 
 a mole which has changed in appearance and which is also itching or 
bleeding 
 
Summary of: (8) Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews T et al. The 
prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. 2007. 
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Genetic factors include; Fitzpatrick skin type I (often burns and rarely tans), red hair, 
blue eyes and freckles, >100 naevi, the presence of atypical naevi and a personal or 
family history of melanoma.   
 
Table 5. 
 
Skin Photo types  
 
Skin Type Typical features Tanning ability 
Type I Tends to have freckles, red 
or fair hair, and blue or 
green eyes. 
Often burns, rarely tans. 
Type II Tends to have light hair, 
and blue or brown eyes. 
Usually burns, sometimes 
tans. 
Type III Tends to have brown hair 
and eyes. 
Sometimes burns, usually 
tans. 
Type IV Naturally black-brown 
skin. Often has dark brown 
eyes and hair. 
Rarely burns, often tans. 
Type V Naturally black-brown 
skin. Often has dark brown 
eyes and hair. 
 
Type VI Naturally black-brown 
skin. Usually has black-
brown eyes and hair. 
 
Adapted from: Fitzpatrick T B 1975 Soleil et peau J. Med. Esthet. 2 33-4. 
 
 
Atypical naevi are defined as moles with 3 or more of the following features; 
diameter >5mm, irregular shape, blurred outline, irregular margins, varying shades of 
colour and flat and bumpy components) Similarly, patients with Familial Atypical 
Multiple Mole-Melanoma syndrome (FAMMM), defined as one or more first-degree 
or second-degree relative with MM, the presence of numerous, often >50 naevi, some 
of which are atypical and naevi that are dysplastic on histopathology, are at higher 
risk of MM. 
 (18)
  Although the majority of melanoma occurs in patients with fair skin 
type, a rare subset of melanoma known as acral lentiginous melanoma (i.e. affecting 
the acral skin of the hands and feet) is more common in African-American skin types.  
Because this type of melanoma presents at a later stage owing to the site, the 
prognosis is often poor 
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UVR exposure 
 
The most important environmental cause of skin cancer is exposure to the sun.  
Patients should be asked about sun exposure including use of sunbeds, sunny holidays 
and blistering sunburns in childhood as well as the use of sun protection and 
sunscreen and sun protection measures. Ultraviolet radiation (UVR) is associated with 
the development of melanoma 
(19)
 and can be broadly categorised into UVA (315-400 
nm), UVB (280-315 nm), and UVC (100-280 nm). All UVC and most UVB 
wavelengths are blocked by the ozone layer with only a fraction of UVB and all UVA 
reaching the Earth’s surface.  Indoor tanning or sunbeds have become the main non-
solar source of exposure to UV light in light-skinned individuals. Indoor tanning 
equipment mainly emits UVA light with a small fraction (<5%) in the UVB range.   
Indoor tanning devices and the UV light spectrum were classified as a group 1 
carcinogen to humans in 2009. 
(20)
 
 
A study published in 2011 
(21)
 estimated that approximately 86% of malignant 
melanomas in the UK in 2010 were linked to exposure to UVR from the sun and 
sunbeds.  Similarly, a large meta-analysis published in 2012 
(22)
 based on 27 studies 
demonstrated that ever use of sunbeds was associated with a summary relative risk of 
1.2 (95% CI 1.08-1.34).  Furthermore, 13 of these studies demonstrated an overall 
summary relative risk of 1.87 (95% CI 1.41-2.48) with first use of sunbeds before 35 
years. 
 (22)
 It is hopeful that the Sunbeds Act (NI) 2011 
(23)
 will lead to a reduction in 
the incidence of melanoma in future years. 
 
Examination 
 
When assessing a patient with a new or changing naevus ideally a total-body skin 
examination should be performed.  Not only does this increase the chances of 
diagnosing an incidental melanoma/melanoma in-situ,
 (24)
 but it also allows the 
clinician to compare the morphology of the index lesion to that of other naevi and 
recognise the so-called ‘ugly duckling’ sign. (17) Crucial to a good skin examination is 
a well-lit examination room.  Ideally it would be good practice to perform a total body 
examination, taking account of the number of naevi present on the patient's skin and 
the using the ABCDE criteria used to differentiate early melanomas from benign 
naevi.  If melanoma is suspected, the patient should also be examined for the presence 
of lymphadenopathy in all lymph node groups, particularly the draining basin 
corresponding to the lesion.   
 
Dermoscopy and Photography 
 
Dermoscopy or epiluminescence microscopy can be used by trained physicians to 
assess the patient’s naevi rapidly.   
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Figure 2. 
 
 
 
This involves using either a non-polarised light and surface oil or a polarised 
magnifying lens with no oil medium, to examine a lesion. 
 
Useful adjuncts to management include serial photography techniques, such as ‘mole-
mapping’ using dermoscopy. Computerized image analysis can then store images of 
the lesions and makes them available for comparison over time e.g. for monitoring 
patients in FAMM. 
 
 
Dermatoscopy for triage (teledermatology) 
With increasing constraints on the provision of healthcare and an increased volume of 
suspected skin cancer referrals to secondary care, teledermatology may be a useful 
triaging tool and is used with increasing frequency in Dermatology.  The clinician in 
primary care is responsible for taking high quality photographs of the index lesion and 
corresponding digital dermoscopy images along with a clinical history (usually on an 
agreed proforma) to allow the dermatologist to triage the patient more appropriately.  
This ‘store and forward’ type of teledermatology is particularly useful as it lends itself 
to triage as it allows the clinician to review the stored images at a convenient time and 
place. It is important that if teledermatology is used it should complement the existing 
service and be part of an integrated local dermatology service. 
(25)
 In addition 
guidance on patient consent and information governance should be in place to 
monitor the effectiveness and safety of these pathways but also to protect patient 
confidentiality and ensure safe transfer of clinical information particularly 
photographic images.
(25)
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Referral pathways and management 
 
If a patient with a suspected malignant melanoma is seen in primary care there are 
clear referral pathways for urgent/red flag referral to secondary care. The National 
Institute for Health and Care Excellence (NICE) 
(16)
 ‘Referral Guidelines for 
Suspected Cancer’ state that ‘an urgent referral to a dermatologist or other suitable 
specialist with experience of melanoma diagnosis should be made and excision in 
primary care avoided.’(16)    
 
The Northern Ireland Cancer Network (NICaN)  
(15)
 has issued clear guidance for 
referral of suspected skin cancer into secondary care 
(http://www.cancerni.net/files/file/ReferralGuidanceMay2007.pdf).  As mentioned 
previously, a changing lesion or a score of 3 or more in the Glasgow 7-point checklist 
is suspicious of melanoma. The importance of clear accurate clinical information 
cannot be emphasized enough as this allows patients to be triaged appropriately and 
therefore seen in a timely manner.  Patients should be referred into secondary care as 
a ‘red flag’ and are seen within 2-weeks.  It is emphasised in the NICE Guidance that 
such lesions should not be excised in primary care and strongly recommended that 
incisional or incomplete excisions are avoided, particularly because of sampling error 
and the risk of inaccurate diagnosis. 
(8)
 All excised skin specimens even those 
regarded as benign should be sent for histopathological analysis.
(16)
 The practitioner 
should also maintain a ‘fail-safe’ log of all procedures performed with details of the 
outcome and action following histological diagnosis.    
 
 
 
Other considerations 
 
Secondary prevention 
 
Following a diagnosis of melanoma secondary prevention is paramount as a history of 
melanoma increases the risk of a metachronous melanoma.  Patients should be 
counseled on the importance of effective sun protection measures, avoidance of 
sunbeds and the correct use of sunscreen. It is recommended that patients should use a 
sun protection factor (SPF) of 20-30 and five star ultraviolet A (UVA). 
 (8)
 Regular 
self-examination of the skin should be encouraged.  Useful resources are available to 
download from the British Association of Dermatologists website 
(http://www.bad.org.uk). 
(26)
 
 
Vitamin D 
 
Once patients are diagnosed with melanoma, they are asked to use sun protection 
measures.  The reason for this is two-fold; to reduce the risk of a second melanoma 
and to reduce the risk of immunosuppression from UV light.  Often patients through 
fear of recurrence or worry over developing another skin cancer will completely sun 
avoid putting them at high risk of Vitamin D deficiency. This not only has 
implications for bone health but has also been associated with poorer survival 
following melanoma
.
.
(27)
 As the amount of time required for safe exposure to sunlight 
in order to promote skin stores of Vitamin D remains controversial, currently the 
advice for patients with a history of melanoma is still to sun protect and if concerned 
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about Vitamin D deficiency to take supplements.
(28)
 Current guidance from NHS 
Choices recommends up to 1000 IU (25 micrograms) per day
(29)
.  The Melanoma 
Genetics Consortium
(30)
 currently recommend that patients with a history of 
melanoma consider taking between 600-1000 IU of vitamin D per day and that the 
dose should be discussed with their doctor, with consideration made for measuring 
baseline Vitamin D. It is also prudent to check baseline renal function and bone 
profile prior to initiating therapy.  Rarely Vitamin D supplementation can unmask 
primary hyperparathyroidism so serum calcium levels should be checked one month 
after starting supplementation. It is advisable to wait at least 6 months after starting 
supplements before rechecking Vitamin D levels. 
 
Summary and overview 
 
In summary, the incidence of melanoma continues to rise. Health promotion 
measures, which highlight the risks of excessive sun exposure and use of sun beds are 
very important. It is also essential that there is ongoing education for clinicians in 
primary care on the early signs of melanoma and continued awareness of the 
appropriate referral pathway for suspicious lesions. Early detection is the key factor 
determining a good prognosis. 
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